MediWound Ltd Dossier
Qualitative Analysis
Business overview
MediWound Ltd. (NASDAQ: MDWD) is a fully-integrated, commercial-stage biopharmaceutical company headquartered in Yavne, Israel, specializing in next-generation enzymatic therapeutics for tissue repair and regeneration. The company's patented proteolytic enzyme technology forms the basis of its clinical pipeline and commercial offerings. Its flagship commercial product, NexoBrid, is an FDA-approved orphan biologic designed for the rapid, non-surgical removal of eschar (dead tissue) in patients with deep partial- and full-thickness thermal burns. MediWound's advanced clinical pipeline includes EscharEx, a bioactive enzymatic therapy currently in a Phase III clinical trial (VALUE study) for the debridement of chronic venous leg ulcers (VLUs), and MW005, a topical biological candidate for the treatment of non-melanoma skin cancers.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the late-stage investigational biologic EscharEx for chronic wound debridement. This includes executing the global Phase III VALUE trial in venous leg ulcers (VLUs) across approximately 40 sites in the U.S., Europe, and Israel, and expanding clinical development into diabetic foot ulcers (DFUs) and pressure ulcers (PUs).
Expected impact: Establishes EscharEx as a potential new standard of care in chronic wound debridement, targeting a $2.5 billion global market opportunity.
Expanding and operationalizing the NexoBrid manufacturing facility to increase production capacity sixfold to support growing global commercial demand and national preparedness stockpiling.
Expected impact: Eases production bottlenecks, supports the 10-year BARDA contract, and enables commercial supply scale-up globally.
Leveraging partnerships with major global wound care and medical technology companies to support clinical trials and commercial distribution. This includes collaborations with Vericel in North America, and research collaborations for EscharEx with Medline, Coloplast/Kerecis, Convatec, Essity, Mölnlycke, Solventum, B. Braun, and MIMEDX.
Expected impact: Ensures consistent wound management across clinical sites, optimizes patient outcomes, and builds a robust commercial launchpad for EscharEx.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Mölnlycke made a $15 million strategic investment in MediWound in July 2024. The partnership grants Mölnlycke specific rights, including representation on MediWound's R&D Committee, and participation rights in potential strategic partnership discussions and M&A processes under certain circumstances.
Terms: $15 million equity investment through a private investment in public equity (PIPE) transaction.
Vericel serves as the exclusive distributor of NexoBrid in North America. In April 2026, Vericel was awarded a 10-year BARDA contract valued at up to $197 million to support NexoBrid procurement, emergency preparedness, and next-generation development.
Terms: Vericel's BARDA contract is valued at up to $197 million, which will drive procurement and development revenues for NexoBrid, with initial procurement starting in H2 2026.
Medline joined MediWound's EscharEx clinical development program in early 2026, completing a network of collaborations that includes all major advanced wound care companies relevant to the program.
Terms: Terms of the research collaboration were not publicly disclosed.